Pharmacogenomics in Cytotoxic Chemotherapy of Cancer
- PMID: 36068461
- DOI: 10.1007/978-1-0716-2573-6_4
Pharmacogenomics in Cytotoxic Chemotherapy of Cancer
Abstract
Pharmacogenetic testing in patients with cancer requiring cytotoxic chemotherapy offers the potential to predict, prevent, and mitigate chemotherapy-related toxicities. While multiple drug-gene pairs have been identified and studied, few drug-gene pairs are currently used routinely in the clinical status. Here we review what is known, theorized, and unknown regarding the use of pharmacogenetic testing in cancer.
Keywords: Cancer; Chemotherapy; Efficacy; Pharmacogenetics; Pharmacogenomics; Toxicity.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Weng L, Zhang L, Peng Y et al (2013) Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics 14(3):315–324 - PubMed
-
- FDA (2017) Table of pharmacogenomic biomarkers in drug labeling. https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm . Accessed 2 Feb 2018
-
- de Beaumais TA, Jacqz-Aigrain E (2012) Intracellular disposition of methotrexate in acute lymphoblastic leukemia in children. Curr Drug Metab 13(6):822–834 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
